Differences in Adverse Event Rates Found After Generic Commercialization of 3 Drugs
Immediate or delayed differences in adverse event rates were seen after generic commercialization of 3 antihypertensive drugs.
Immediate or delayed differences in adverse event rates were seen after generic commercialization of 3 antihypertensive drugs.
The agency will now give priority reviews to new generic drugs until there are at least 3 available.
According to Mylan, the first generic version of EpiPen® will be distributed in several weeks in an attempt to further lower the costs of attaining this life-saving medication.